.omega.-cycloalkyl-prostaglandin E1 derivatives
US6235780A · kind A · utility
22Cited by
7References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 19, 1999 |
| Grant date | May 22, 2001 |
| Priority date | — |
| Expiry date | Jul 19, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/557
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
##STR1## PA1 (wherein R.sup.1 is OH etc.; X is Cl, F; R.sup.2 is H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl which may be substituted; n is 0-4.), non-toxic salts thereof or cyclodextrin clathrates thereof can strongly bind on EP.sub.2 subtype receptor. Therefore, they are useful for the prevention and/or treatment of immunological diseases (autoimmune diseases, post-transplantation graft rejection etc.), asthma, abnormal bone formation, neuronal cell death, hepatopathy, abortion, premature birth or retina neuropathy (e.g. glaucoma) etc.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.